Why CAR-NK cell?

CAR-NK therapy combines the innate, rapid tumor-killing power of natural killer (NK) cells with the precision of chimeric antigen receptors (CARs) — a promising, potentially safer “off-the-shelf” approach to target malignant glioma (high-grade/GBM)

  • High unmet need: Malignant gliomas progress rapidly, recur frequently, and affect both adults and children.

  • Targetable and potent: Many gliomas express antigens (e.g., GD2); CAR-NKs combine antigen precision with NK cells’ rapid tumor-killing—even against MHC-low tumors.

  • Accessible and safer: Off-the-shelf CAR-NKs shorten time-to-treatment and carry lower risks of severe CRS/GVHD; reimbursement programs (e.g., V147) can significantly improve patient access.

Why we focus on CAR-NK for malignant glioma?

  • Development of CAR for NK Cell

    • GD2는 신경계 기원 종양에서 높게 발현되는 종양 특이적 표면 항원

    • FDA 승인 항체(Dinutuximab)의 공식 표적으로 임상적 타당성 검증

    • GD2를 인식하는 NK-optimized CAR 구조를 적용하여 astrocytoma를 포함한 난치성 신경계 종양에 효과적인 치료효과를 확보

  • 종양제거관련 세포내 신호전달 확인

Research Status